Pfizer (PFE) Other Operating Expenses (2010 - 2017)
Pfizer (PFE) posted quarterly Other Operating Expenses of -$7.0 billion for Q4 2017, up 14.67% year-over-year from -$6.1 billion in Q4 2016, and down 27.39% quarter-over-quarter from -$5.5 billion in Q4 2017.
Pfizer (PFE) Other Operating Expenses (2010 - 2017) Analysis & Trends
Pfizer (PFE) has reported Other Operating Expenses for 8 consecutive years, with -$7.0 billion the latest figure, recorded in Q4 2017.
- In Q4 2017, Other Operating Expenses rose 14.67% year-over-year to -$7.0 billion; the TTM figure through Sep 2018 stood at -$7.0 billion (up 71.09% YoY), while the FY2017 annual figure was -$22.7 billion, up 7.25% from the prior year.
- Other Operating Expenses eased to -$7.0 billion in Q4 2017 per PFE's latest filing, from -$5.5 billion in the prior quarter.
- Across five years, Other Operating Expenses topped out at $1.1 billion in Q2 2013 and bottomed at -$8.2 billion in Q4 2016.
- Historically, Other Operating Expenses has averaged -$3.8 billion across 5 years, with a median of -$5.1 billion in 2015.
- Annual changes were most pronounced in 2013 — Other Operating Expenses soared 255.52% — and 2015, when it slumped 9715.09%.
- Pfizer's Other Operating Expenses stood at $18.0 million in 2013, then surged by 194.44% to $53.0 million in 2014, then slumped by 14339.62% to -$7.5 billion in 2015, then retreated by 8.84% to -$8.2 billion in 2016, then grew by 14.67% to -$7.0 billion in 2017.
- Business Quant data shows PFE's Other Operating Expenses at -$7.0 billion in Q4 2017, -$5.5 billion in Q4 2017, and -$5.3 billion in Q3 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2017 | -7.01 Bn |
| Oct 1, 2017 | -5.50 Bn |
| Jul 2, 2017 | -5.31 Bn |
| Apr 2, 2017 | -5.21 Bn |
| Dec 31, 2016 | -8.21 Bn |
| Oct 2, 2016 | -6.00 Bn |
| Jul 3, 2016 | -5.33 Bn |
| Apr 3, 2016 | -5.07 Bn |
| Dec 31, 2015 | -7.55 Bn |
| Jun 28, 2015 | -5.10 Bn |
| Mar 29, 2015 | -4.97 Bn |
| Jun 29, 2014 | 53.00 Mn |
| Mar 30, 2014 | -623.00 Mn |
| Dec 31, 2013 | 18.00 Mn |
| Sep 29, 2013 | -411.00 Mn |
| Jun 30, 2013 | 1.07 Bn |
| Mar 31, 2013 | -145.00 Mn |
| Dec 31, 2012 | -758.00 Mn |
| Sep 30, 2012 | -937.00 Mn |
| Jul 1, 2012 | -688.00 Mn |